ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand StoryNews List
-
Diabetes and Metabolic Disorders: The Approval of Teplizumab David Orchard-Webb
June 23, 2025Teplizumab, the first disease-modifying therapy for Type 1 diabetes, delays disease onset by ~4 years in high-risk individuals. Priced at $194,000 per course, it redefines early intervention despite cost barriers.
Pharma Sources Insight January 2025
